Dr Ho-Tak Lau is a Sr. Scientist at Bristol Myers Squibb where he is exploring the uses of mass spec-based methodologies in cell therapies process development. Before joining BMS, Ho-Tak worked as a mass spec proteomics researcher at the University of Washington. Ho-Tak holds his Ph.D in Life and Health Sciences from the University of Ulster, Northern Ireland.